Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Meropenem Using Serum Creatinine and Cystatin-C

NCT07818265 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.

NCT NCT07818265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07818265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Meropenem Using Serum Creatinine and Cystatin-C
Lead sponsor
King Faisal Specialist Hospital & Research Center
Phase
Observational
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
July 9, 2027
Enrollment
304 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, bacterial infections, nephrotoxicity, renal impairment